<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>08436593831110</udiDi>
    <basicUdiDi>843659383ULA823NA</basicUdiDi>
    <tradeName>Ulkox 30 g muestra</tradeName>
    <deviceName>Ulkox tube</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>M04040501</emdnCode>
    <emdnDescription>HYDROGEL DRESSINGS, NON-COMBINED</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1291485</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-03T11:54:42.762Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593831073</udiDi>
    <basicUdiDi>843659383OLA923KZ</basicUdiDi>
    <tradeName>Oleoabrax 30 g muestra</tradeName>
    <deviceName>Oleoabrax tube</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>M04040501</emdnCode>
    <emdnDescription>HYDROGEL DRESSINGS, NON-COMBINED</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1291481</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-03T11:54:41.938Z</lastUpdated>
  </row>
  <row>
    <udiDi>05391536010256</udiDi>
    <basicUdiDi>843659383XIA643NC</basicUdiDi>
    <tradeName>Tasectan AF</tradeName>
    <deviceName>XILAPLUS AF sachets without flavour</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode></emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1312070</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-03T11:50:34.452Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593831349</udiDi>
    <basicUdiDi>843659383UTA433QH</basicUdiDi>
    <tradeName>Utipro Plus AF</tradeName>
    <deviceName>Utipro Plus AF tablets</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0499</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>AB pazarı için değil</deviceStatus>
    <reference>000000</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:41.165Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593831271</udiDi>
    <basicUdiDi>843659383XIA623N6</basicUdiDi>
    <tradeName>Direxol</tradeName>
    <deviceName>XILAPLUS AF capsules</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1313112</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:39.960Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830755</udiDi>
    <basicUdiDi>843659383TAS123LX</basicUdiDi>
    <tradeName>Tasectan 500 mg</tradeName>
    <deviceName>Tasectan capsules</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G99</emdnCode>
    <emdnDescription>GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1311364</reference>
    <placedOnMarketCountry>Belgium</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:33.958Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830625</udiDi>
    <basicUdiDi>843659383XIA633N9</basicUdiDi>
    <tradeName>Xilaplus AF sobres sin aroma</tradeName>
    <deviceName>Xilaplus AF sachets with flavour</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>AB pazarı için değil</deviceStatus>
    <reference>1310678</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:32.750Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830304</udiDi>
    <basicUdiDi>843659383TAS123LX</basicUdiDi>
    <tradeName>Tasectan 500 mg</tradeName>
    <deviceName>Tasectan capsules</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G99</emdnCode>
    <emdnDescription>GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1308534</reference>
    <placedOnMarketCountry>Belgium</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:31.546Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830298</udiDi>
    <basicUdiDi>843659383TAS133M2</basicUdiDi>
    <tradeName>Tasectan 250 mg</tradeName>
    <deviceName>Tasectan sachets</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G99</emdnCode>
    <emdnDescription>GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1308533</reference>
    <placedOnMarketCountry>Belgium</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:30.344Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830151</udiDi>
    <basicUdiDi>843659383TAS123LX</basicUdiDi>
    <tradeName>Tasectan 15 capsules</tradeName>
    <deviceName>Tasectan capsules</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G99</emdnCode>
    <emdnDescription>GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1308500</reference>
    <placedOnMarketCountry>Greece</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:23.165Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830144</udiDi>
    <basicUdiDi>843659383TAS133M2</basicUdiDi>
    <tradeName>Tasectan 20 sachets</tradeName>
    <deviceName>Tasectan sachets</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G99</emdnCode>
    <emdnDescription>GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1308499</reference>
    <placedOnMarketCountry>Greece</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:21.956Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830090</udiDi>
    <basicUdiDi>843659383TAS133M2</basicUdiDi>
    <tradeName>Gelenterum 250 mg</tradeName>
    <deviceName>Tasectan sachets</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G99</emdnCode>
    <emdnDescription>GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1308490</reference>
    <placedOnMarketCountry>Italy</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:20.744Z</lastUpdated>
  </row>
  <row>
    <udiDi>08436593830052</udiDi>
    <basicUdiDi>843659383XIA653NF</basicUdiDi>
    <tradeName>Xilaplus AF comprimidos</tradeName>
    <deviceName>Xilaplus AF tablets</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0402</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR APPETITE CONTROL AND REDUCTION OF INTESTINAL ABSORPTION</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1291414</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:33:19.555Z</lastUpdated>
  </row>
  <row>
    <udiDi>08006540717158</udiDi>
    <basicUdiDi>843659383UTA423QE</basicUdiDi>
    <tradeName>URI-CRAN FORTE  AF 15 capsules</tradeName>
    <deviceName>UTIPRO PLUS AF capsules</deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0499</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED GASTROINTESTINAL DEVICES - OTHER</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1311830</reference>
    <placedOnMarketCountry>Belgium</placedOnMarketCountry>
    <lastUpdated>2026-06-30T10:23:22.162Z</lastUpdated>
  </row>
  <row>
    <udiDi>D-1313022UN</udiDi>
    <basicUdiDi>B-1313022UN</basicUdiDi>
    <tradeName>CYS-CONTROL ULTRA</tradeName>
    <deviceName></deviceName>
    <manufacturerName>Noventure S.L.U.</manufacturerName>
    <manufacturerSrn>ES-MF-000000797</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIa</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode></emdnCode>
    <emdnDescription></emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1313022</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-06-15T23:46:14.127Z</lastUpdated>
  </row>
</eudamedExport>